Overview

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Antibodies, Monoclonal
Brodalumab
Ustekinumab